Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease - PubMed (original) (raw)
Affiliations
- PMID: 7581150
Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease
K R Schultz et al. Bone Marrow Transplant. 1995 Aug.
Abstract
Increased understanding of minor histocompatibility complex (MiHC) antigen presentation to donor T cells may permit methods to modulate graft-versus-host disease (GVHD), a major complication of allogeneic bone marrow transplantation (BMT). Previously, we described the importance of B cells as antigen presenting cells in T cell responses to a virally induced murine leukemia. Using a B cell deficient mouse model in which mice receive either control rabbit immunoglobulin (RIgG) or rabbit anti-IgM mu chain from birth (B cell deficient), we evaluated whether B cells were necessary for T cell responses to MiHC and the induction of GHVD. Normal and B cell deficient C57BL/6 (H-2b) mice were primed with BALB.B (H-2b; MiHC incompatible) spleen cells and evaluated > 4 weeks later in vitro. While splenic or lymph node T cells obtained from BALB.B primed control C57BL/6 mice demonstrated strong in vitro proliferative responses to MiHC mismatched targets, B cell deficient hosts were markedly reduced to 14-42% of controls. Similarly, a strong MiHC specific cytolytic T cell response was observed in control C57BL/6 mice (53-100% specific cytotoxicity) whereas B cell depleted recipients had no activity (< or = 5% specific lysis). The role of B cells in GVHD was evaluated using a MiHC disparate mouse model (LP/J donor into C57BL/6 recipient). We found that 12% of B cell depleted recipient mice receiving B cell depleted donor cells developed GVHD compared to 50% of RIgG control mice. B cell depletion of donor cells only, resulted in a similar result with 0% of mice receiving B cell depleted donor cells developing GVHD compared to 38% of controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M, Wettstein PJ, Korngold R. Berger M, et al. Transplantation. 1994 Apr 15;57(7):1095-102. Transplantation. 1994. PMID: 7909395 - A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R. Choksi S, et al. Biol Blood Marrow Transplant. 2004 Oct;10(10):669-80. doi: 10.1016/j.bbmt.2004.06.005. Biol Blood Marrow Transplant. 2004. PMID: 15389433 - Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR. Gendelman M, et al. Biol Blood Marrow Transplant. 2003 Dec;9(12):742-52. doi: 10.1016/j.bbmt.2003.09.007. Biol Blood Marrow Transplant. 2003. PMID: 14677113 - Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review. - Syngeneic or autologous graft-versus-host disease.
Santos GW. Santos GW. Int J Cell Cloning. 1989 Mar;7(2):92-9. doi: 10.1002/stem.5530070203. Int J Cell Cloning. 1989. PMID: 2656886 Review.
Cited by
- Ikaros expression is associated with an increased risk of chronic graft-versus-host disease.
Pereira AD, de Molla VC, Fonseca ARBM, Tucunduva L, Novis Y, Pires MS, Popi AF, Arrais-Rodrigues CA. Pereira AD, et al. Sci Rep. 2023 May 25;13(1):8458. doi: 10.1038/s41598-023-35609-3. Sci Rep. 2023. PMID: 37231055 Free PMC article. - Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.
Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Baumrin E, et al. J Am Acad Dermatol. 2024 Jan;90(1):1-16. doi: 10.1016/j.jaad.2022.12.024. Epub 2022 Dec 23. J Am Acad Dermatol. 2024. PMID: 36572065 Review. - Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
Buxbaum NP, Socié G, Hill GR, MacDonald KPA, Tkachev V, Teshima T, Lee SJ, Ritz J, Sarantopoulos S, Luznik L, Zeng D, Paczesny S, Martin PJ, Pavletic SZ, Schultz KR, Blazar BR. Buxbaum NP, et al. Blood Adv. 2023 Sep 12;7(17):4886-4902. doi: 10.1182/bloodadvances.2022007611. Blood Adv. 2023. PMID: 36322878 Free PMC article. - Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.
Michniacki TF, Choi SW, Peltier DC. Michniacki TF, et al. Handb Exp Pharmacol. 2022;272:209-243. doi: 10.1007/164_2021_544. Handb Exp Pharmacol. 2022. PMID: 34628553 Free PMC article. - Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients.
Serpenti F, Lorentino F, Marktel S, Milani R, Messina C, Greco R, Girlanda S, Clerici D, Giglio F, Liberatore C, Farina F, Mastaglio S, Piemontese S, Guggiari E, Lunghi F, Marcatti M, Carrabba MG, Bernardi M, Bonini C, Assanelli A, Corti C, Peccatori J, Ciceri F, Lupo-Stanghellini MT. Serpenti F, et al. Front Oncol. 2021 Jul 22;11:705568. doi: 10.3389/fonc.2021.705568. eCollection 2021. Front Oncol. 2021. PMID: 34367991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials